Atriance (nelarabine)
pCPA File Number:
22515
Negotiation Status:
Negotiations were not pursued
Indication(s):
Intermediate- or high-risk T-cell acute lymphoblastic leukemia (T-ALL), addition to front-line multi-agent therapy of pediatric, adolescent, and young adult (AYA) patients (aged 1 year to 30 years at diagnosis)
Sponsor/Manufacturer:
Sandoz Canada Inc.
CDA-AMC Project Number:
PC0307-000
pCPA Engagement Letter Issued:
Not Applicable
Negotiation Process Concluded: